Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ronald Shazer"'
Autor:
David Goldstein, Anna Spreafico, Ilan Weinreb, Trevor J. Pugh, Scott V Bratman, Bayardo Perez-Ordonez, Aaron R Hansen, Lillian Siu, Antony Tin, Alexey Aleshin, Amy Prawira, Jonathan Irish, John de Almeida, Douglas Chepeha, Stephen Smith, Marc Oliva, Daniel V Araujo, J. Javier Diaz-Mejia, Peter Olson, Tina Shek, Andrew Hope, Dax Torti, Jeffrey P. Bruce, Ben X. Wang, Anthony Fortuna, Hirak Der-Torossian, Ronald Shazer, Nickolas Attanasio, Qingyan Au, Jordan Feeney, Himanshu Sethi, Isan Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/0c91b22ec6d04b31bb0d153a425dbaed
Autor:
Kai He, David Berz, Shirish M. Gadgeel, Wade T. Iams, Debora S. Bruno, Collin M. Blakely, Alexander I. Spira, Manish R. Patel, David M. Waterhouse, Donald A. Richards, Anthony Pham, Robert Jotte, David S. Hong, Edward B. Garon, Anne Traynor, Peter Olson, Lisa Latven, Xiaohong Yan, Ronald Shazer, Ticiana A. Leal
Publikováno v:
Journal of Thoracic Oncology.
Autor:
Pavlos Msaouel, Sangeeta Goswami, Peter F. Thall, Xuemei Wang, Ying Yuan, Eric Jonasch, Jianjun Gao, Matthew T. Campbell, Amishi Yogesh Shah, Paul Gettys Corn, Alda L. Tam, Kamran Ahrar, Priya Rao, Kanishka Sircar, Lorenzo Cohen, Sreyashi Basu, Fei Duan, Sonali Jindal, Yuwei Zhang, Hong Chen, Shalini S. Yadav, Ronald Shazer, Hirak Der-Torossian, James P. Allison, Padmanee Sharma, Nizar M. Tannir
Publikováno v:
Science Translational Medicine. 14
The accumulation of immune-suppressive myeloid cells is a critical determinant of resistance to anti–programmed death-1 (PD-1) therapy in advanced clear cell renal cell carcinoma (ccRCC). In preclinical models, the tyrosine kinase inhibitor sitrava
Autor:
Antony Tin, Lillian L. Siu, Nickolas Attanasio, David P. Goldstein, Tina Shek, Bayardo Perez-Ordonez, J. Javier Díaz-Mejía, Ronald Shazer, Anna Spreafico, Douglas B. Chepeha, Ben X Wang, Ilan Weinreb, Hirak Der-Torossian, Andrew Hope, Aaron R. Hansen, Daniel Vilarim Araujo, Qingyan Au, Amy Prawira, John R. de Almeida, Alexey Aleshin, Jordan Feeney, Marc Oliva, Peter Olson, Stephen M. Smith, Jonathan C. Irish, Jeff Bruce, Anthony Fortuna, Himanshu Sethi, Isan Chen, Trevor J. Pugh, Dax Torti, Scott V. Bratman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundSitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated macrophages ratio in the tumor microenvironment and have synergistic ant
Autor:
Lifu Zhang, Yu-Hsuan Liu, Jun Zhu, Stephen D. Smith, G.S. Nowakowski, Yuqin Song, Manoj A. Jivani, Ronald Shazer, Isabel Han, Owen A. O'Connor, Wen Luo
Publikováno v:
Hematological Oncology. 37:70-70
Publikováno v:
Blood. 132:4207-4207
Background Drugs that have benefited a subset of patients but discontinued for development may be rescued through identification of a biomarker predictive of response. Enzastaurin, a potent and selective inhibitor of protein kinase C-β, improved PFS